Development Pipeline

Today, our research efforts are dedicated to advancing a diverse pipeline of innovative therapies for solid tumors and blood-related cancers.
Learn about our development programs by selecting an agent below or click to explore our interactive pipeline.

Brentuximab vedotin

an investigational antibody–drug conjugate directed to CD30

  • Phase 1
  • Phase 2
  • Phase 3

View Program